Michael Berk
Michael Berk
Verified email at deakin.edu.au - Homepage
TitleCited byYear
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors
M Berk, F Kapczinski, AC Andreazza, OM Dean, F Giorlando, M Maes, ...
Neuroscience & biobehavioral reviews 35 (3), 804-817, 2011
8752011
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
F Ng, M Berk, O Dean, AI Bush
International Journal of Neuropsychopharmacology 11 (6), 851-876, 2008
8562008
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of …
LN Yatham, SH Kennedy, SV Parikh, A Schaffer, S Beaulieu, M Alda, ...
Bipolar disorders 15 (1), 1-44, 2013
8142013
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness
M Maes, P Galecki, YS Chang, M Berk
Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (3), 676-692, 2011
7212011
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of …
LN Yatham, SH Kennedy, A Schaffer, SV Parikh, S Beaulieu, ...
Bipolar disorders 11 (3), 225-255, 2009
6902009
So depression is an inflammatory disease, but where does the inflammation come from?
M Berk, LJ Williams, FN Jacka, A O’Neil, JA Pasco, S Moylan, NB Allen, ...
BMC medicine 11 (1), 200, 2013
6342013
Association of Western and traditional diets with depression and anxiety in women
FN Jacka, JA Pasco, A Mykletun, LJ Williams, AM Hodge, SL O'Reilly, ...
American Journal of Psychiatry 167 (3), 305-311, 2010
5692010
N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial
M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, ...
Biological psychiatry 64 (5), 361-368, 2008
4862008
Bipolar disorder
I Grande, M Berk, B Birmaher, E Vieta
The Lancet 387 (10027), 1561-1572, 2016
4692016
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders
I Pacchiarotti, DJ Bond, RJ Baldessarini, WA Nolen, H Grunze, RW Licht, ...
American Journal of Psychiatry 170 (11), 1249-1262, 2013
4592013
N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial
M Berk, DL Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, ...
Biological psychiatry 64 (6), 468-475, 2008
4462008
The chemistry and biological activities of N-acetylcysteine
Y Samuni, S Goldstein, OM Dean, M Berk
Biochimica et Biophysica Acta (BBA)-General Subjects 1830 (8), 4117-4129, 2013
4352013
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
O Dean, F Giorlando, M Berk
Journal of psychiatry & neuroscience: JPN 36 (2), 78, 2011
3822011
The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications
S Moylan, M Maes, NR Wray, M Berk
Molecular psychiatry 18 (5), 595, 2013
3692013
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways
M Maes, M Berk, L Goehler, C Song, G Anderson, P Gałecki, B Leonard
BMC medicine 10 (1), 66, 2012
3672012
The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders
M Tohen, E Frank, CL Bowden, F Colom, SN Ghaemi, LN Yatham, ...
Bipolar disorders 11 (5), 453-473, 2009
3632009
Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.
J Segal, M Berk, S Brook
Clinical Neuropharmacology, 1998
3541998
Intervention in individuals at ultra-high risk for psychosis: a review and future directions.
PD McGorry, B Nelson, GP Amminger, A Bechdolf, SM Francey, G Berger, ...
The Journal of clinical psychiatry, 2009
3332009
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
S Lavoie, MM Murray, P Deppen, MG Knyazeva, M Berk, O Boulat, ...
Neuropsychopharmacology 33 (9), 2187, 2008
3242008
N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
S Dodd, O Dean, DL Copolov, GS Malhi, M Berk
Expert opinion on biological therapy 8 (12), 1955-1962, 2008
3212008
The system can't perform the operation now. Try again later.
Articles 1–20